PharmaEssentia Corporation, a fully integrated biopharmaceutical company publicly traded and based in Taiwan, is providing this site to help keep healthcare practitioners and affected patients informed of ongoing developments around ropeginterferon alfa-2b (PEG-IFN α-2b). This compound is being studied as a next generation pegylated interferon in hope of addressing the needs of those stricken with polycythemia vera (PV) and other myeloproliferative neoplasm (MPN) disorders.*
Please refer to this site for updates regarding our program and use the attached links to access additional background information into this treatment area.
*The use of interferons in Ph-Myeloproliferative Neoplasms is investigational and off label. Ropeginterferon alfa-2b (P1101) is an investigational drug and is not currently licensed in any country.
Copyright © 2016 PharmaEssentia. All rights reserved.